MYB suppresses differentiation and apoptosis of human breast cancer cells

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Drabsch, Yvette ^a   Ramsay, Robert G ^b   Gonda, Thomas J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; BUTYRIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PROLACTIN; PROTEIN BCL 2; SHORT HAIRPIN RNA; ALPHA TOCOPHEROL; ANTIESTROGEN; BUTYRIC ACID DERIVATIVE; DRUG DERIVATIVE; ESTRADIOL; FULVESTRANT; GREEN FLUORESCENT PROTEIN; PROTEIN C MYB; VITAMIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; ONCOGENE MYB; ANIMAL; BREAST TUMOR; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; BUTYRATES; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TETRADECANOYLPHORBOL ACETATE; VITAMIN E; VITAMINS;

EID: 78650866393     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2614     Document Type: Article

References (66)

1. Mucenski M, McLain K, Kier A, Swerdlow S, Schreiner C, Miller T, Pietryga D, Scott WJ, Potter S. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991, 65:677-689. 10.1016/0092-8674(91)90099-K, 1709592.
2. Westin EH, Gallo RC, Arya SK, Eva A, Souza L, Baluda M, Aaronson S, Wong-Staal F. Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci USA 1982, 79:2194-2198. 10.1073/pnas.79.7.2194, 346157, 6954533.
3. Gonda T, Metcalf D. Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature 1984, 310:249-251. 10.1038/310249a0, 6205276.
4. Wolff L. Myb-induced transformation. Crit Rev Oncog 1996, 7:245-260.
5. Ganter B, Lipsick J. Myb and oncogenesis. Adv Cancer Res 1999, 76:21-60. full_text, 10218098.
6. Ramsay R, Gonda T. MYB function in normal and cancer cells. Nat Rev Cancer 2008, 8:523-534. 10.1038/nrc2439, 18574464.
7. Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ 1992, 3:723-730.
8. Zorbas M, Sicurella C, Bertoncello I, Venter D, Ellis S, Mucenski M, RG R. c-Myb is critical for murine colon development. Oncogene 1999, 18:5821-5830. 10.1038/sj.onc.1202971, 10523863.
9. Thompson M, Rosenthal M, Ellis S, Friend A, Zorbas M, Whitehead R, Ramsay R. c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Research 1998, 58:5168-5175.
10. Alitalo K, Winqvist R, Lin C, de la Chapelle A, Schwab M, Bishop J. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci USA 1984, 81:4534-4538. 10.1073/pnas.81.14.4534, 345625, 6589609.
11. Torelli G, Venturelli D, Coló A, Zanni C, Selleri L, Moretti L, Calabretta B, Torelli U. Expression of c-myb protooncogene and other cell cycle-related genes in normal and neoplastic human colonic mucosa. Cancer Research 1987, 47:5266-5269.
12. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay R, Calabretta B, Zupi G. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001, 158:1289-1299. 1891926, 11290547.
13. Thompson M, Flegg R, Westin E, Ramsay R. Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines. Oncogene 1997, 14:1715-1723. 10.1038/sj.onc.1201007, 9135073.
14. Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T, Phillips W, Dobrovic A, Zupi G, Gonda T, Iacopetta B, Ramsay R. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006, 45:1143-1154. 10.1002/gcc.20378, 16977606.
15. Melani C, Rivoltini L, Parmiani G, Calabretta B, Colombo M. Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Research 1991, 51:2897-2901.
16. Ramsay R, Ciznadija D, Sicurella C, Reyes N, Mitchelhill K, Darcy P, D'Abaco G, Mantamadiotis T. Colon epithelial cell differentiation is inhibited by constitutive c-myb expression or mutant APC plus activated RAS. DNA Cell Biol 2005, 24:21-29. 10.1089/dna.2005.24.21, 15684716.
17. Guérin M, Sheng Z, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990, 5:131-135.
18. Frasor J, Danes J, Komm B, Chang K, Lyttle C, Katzenellenbogen B. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574. 10.1210/en.2003-0567, 12959972.
19. Drabsch Y, Hugo H, Zhang R, Dowhan D, Miao Y, Gewirtz A, Barry S, Ramsay R, Gonda T. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007, 104:13762-13767. 10.1073/pnas.0700104104, 1959456, 17690249.
20. Fang F, Rycyzyn MA, Clevenger CV. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology 2009, 150:1597-1606. 10.1210/en.2008-1079, 2659289, 19036881.
21. Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A, Benimetskaya L. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004, 10:3195-3206. 10.1158/1078-0432.CCR-03-0287, 15131061.
22. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103:843-852. 10.1016/S0092-8674(00)00188-4, 11136970.
23. Ciznadija D, Tothill R, Waterman ML, Zhao L, Huynh D, Yu RM, Ernst M, Ishii S, Mantamadiotis T, Gonda TJ, Ramsay RG, Malaterre J. Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling. Cell Death Differ 2009, 16:1530-1538. 10.1038/cdd.2009.94, 19609274.
24. Sambrook J, Frtisch E, Maniatis T. Molecular Cloning, a Laboratory Manual 1989, Cold Spring Harbor, New York: Cold Spring Harbor Lab Press.
25. Ramsay R, Ishii S, Nishina Y, Soe G, Gonda T. Characterization of alternate and truncated forms of murine c-myb proteins. Oncogene Res 1989, 4:259-269.
26. You H, Yu W, Sanders B, Kline K. RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 2001, 12:471-480.
27. Guilbaud N, Gas N, Dupont M, Valette A. Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 1990, 145:162-172. 10.1002/jcp.1041450122, 2211839.
28. Munster P, Troso-Sandoval T, Rosen N, Rifkind R, Marks P, VM R. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Research 2001, 61:8492-8497.
29. Greenspan P, Mayer E, Fowler S. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985, 100:965-973. 10.1083/jcb.100.3.965, 2113505, 3972906.
30. Merlo G, Graus-Porta D, Cella N, Marte B, Taverna D, Hynes N. Growth, differentiation and survival of HC11 mammary epithelial cells: diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur J Cell Biol 1996, 70:97-105. 10.1016/S0006-3495(96)79552-8, 8793381.
31. Salomoni P, Perrotti D, Martinez R, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Proc Natl Acad Sci USA 1997, 94:3296-3301. 10.1073/pnas.94.7.3296, 20363, 9096387.
32. Frampton J, Ramqvist T, Graf T. v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells. Genes Dev 1996, 10:2720-2731. 10.1101/gad.10.21.2720, 8946913.
33. Taylor D, Badiani P, Weston K. A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev 1996, 10:2732-2744. 10.1101/gad.10.21.2732, 8946914.
34. Lang G, Gombert W, HJ G. A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. Immunology 2005, 114:25-36. 10.1111/j.1365-2567.2004.02073.x, 1782053, 15606792.
35. Peng S, Lalani S, Leavenworth J, Ho I, ME P. c-Maf interacts with c-Myb to down-regulate Bcl-2 expression and increase apoptosis in peripheral CD4 cells. Eur J Immunol 2007, 37:2868-2880. 10.1002/eji.200636979, 17823980.
36. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 1988, 335:835-837. 10.1038/335835a0, 3185713.
37. Bergholtz S, Andersen TO, Andersson KB, Borrebaek J, Luscher B, Gabrielsen OS. The highly conserved DNA-binding domains of A-, B-and c-Myb differ with respect to DNA-binding, phosphorylation and redox properties. Nucleic Acids Res 2001, 29:3546-3556. 10.1093/nar/29.17.3546, 55889, 11522824.
38. Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda T, S I. Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. Proc Natl Acad Sci USA 1989, 86:5758-5762. 10.1073/pnas.86.15.5758, 297709, 2668947.
39. Soldatenkov VA, Prasad S, Voloshin Y, Dritschilo A. Sodium butyrate induces apoptosis and accumulation of ubiquitinated proteins in human breast carcinoma cells. Cell Death Differ 1998, 5:307-312. 10.1038/sj.cdd.4400345, 10200476.
40. Yu W, Israel K, Liao Q, Aldaz C, Sanders B, Kline K. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Research 1999, 59:953-961.
41. de Vente J, Kukoly C, Bryant W, Posekany K, Chen J, Fletcher D, Parker P, Pettit G, Lozano G, Cook PP, et al. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest 1995, 96:1874-1886. 10.1172/JCI118233, 185824, 7560079.
42. Oh I, Reddy E. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 1999, 18:3017-3033. 10.1038/sj.onc.1202839, 10378697.
43. Thompson M, Ramsay R. Myb: an old oncoprotein with new roles. Bioessays 1995, 17:341-350. 10.1002/bies.950170410, 7741726.
44. Clarke M, Kukowska-Latallo J, Westin E, Smith M, Prochownik E. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cell Biol 1988, 8:884-892. 363220, 2832742.
45. Gonda T, Macmillan E, Townsend P, Hapel A. Differentiation state and responses to hematopoietic growth factors of murine myeloid cells transformed by myb. Blood 1993, 82:2813-2822.
46. Mandal M, Kumar R. Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ 1996, 7:311-318.
47. Neuzil J, Weber T, Terman A, Weber C, Brunk U. Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. Redox Rep 2001, 6:143-151. 10.1179/135100001101536247, 11523588.
48. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005, 40:1-13. 10.1016/j.ejmech.2004.10.001, 15642405.
49. Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008, 10:395-398. 10.1007/s12094-008-0221-x, 18628067.
50. Ekert P, Silke J, Vaux D. Caspase inhibitors. Cell Death Differ 1999, 6:1081-1086. 10.1038/sj.cdd.4400594, 10578177.
51. Rosato R, Almenara J, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003, 2:1273-1284.
52. Yu W, Sanders B, Kline K. RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Research 2003, 63:2483-2491.
53. Jänicke R, Sprengart M, Wati M, Porter A. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273:9357-9360. 10.1074/jbc.273.16.9357, 9545256.
54. Villa A, Guzman L, Poptic E, Labhasetwar V, D'Souza S, Farrell C, Plow E, Levy R, DiCorleto P, Topol E. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995, 76:505-513.
55. Kolodziejska K, Noyan-Ashraf M, Nagy A, Bacon A, Frampton J, Xin H, Kotlikoff M, Husain M. c-Myb-dependent smooth muscle cell differentiation. Circ Res 2008, 102:554-561. 10.1161/CIRCRESAHA.105.162628, 18187733.
56. Ess K, Witte D, Bascomb C, Aronow B. Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation. Oncogene 1999, 18:1103-1111. 10.1038/sj.onc.1202387, 10023687.
57. Kumar A, Baker S, Lee C, Reddy E. Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol Cell Biol 2003, 23:6631-6645. 10.1128/MCB.23.18.6631-6645.2003, 193713, 12944488.
58. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
59. Gonda T, Leo P, Ramsay R. Estrogen and MYB in breast cancer: potential for new therapies. Expert Opin Biol Ther 2008, 8:713-717. 10.1517/14712598.8.6.713, 18476782.
60. Zhou G, Zhang J, Wang Z, Chen S, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 2007, 362:959-971. 10.1098/rstb.2007.2026, 2435563, 17317642.
61. De los Santos M, Martinez-Iglesias O, Aranda A. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells. Endocr Relat Cancer 2007, 14:1021-1028. 10.1677/ERC-07-0144, 18045953.
62. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004, 23:21-29. 10.1038/sj.onc.1207020, 14712207.
63. Lessene G, Czabotar P, Colman P. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008, 7:989-1000. 10.1038/nrd2658, 19043450.
64. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681. 10.1038/nature03579, 15902208.
65. Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S, Johnson E, Marsh K, Mitten M, Nimmer P, Roberts L, Tahir S, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg S, Elmore S. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research 2008, 68:3421-3428. 10.1158/0008-5472.CAN-07-5836, 18451170.
66. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009, 113:1982-1991. 10.1182/blood-2008-05-156851, 19060243.